Contact Us
Drug Search Results
More Filters [+]

Lefamulin

Alternative Names: lefamulin, bc-3781, xenleta
Latest Update: 2024-07-18
Latest Update Note: News Article

Product Description

Lefamulin is used to treat community acquired pneumonia (a lung infection that developed in a person who was not in the hospital) caused by certain types of bacteria. Lefamulin is in a class of medications called pleuromutilin antibiotics. It works by slowing the growth or killing bacteria that cause infections.

Mechanisms of Action: 50S Ribosomal Subunit

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Canada | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Italy | Lithuania | Netherlands | Poland | Portugal | Slovakia | Sweden | Taiwan | United States

Approved Indications: Pneumonia, Bacterial | Community-Acquired Infections | Pneumonia

Known Adverse Events: Headache | Insomnia | Hypokalemia | Diarrhea

Company: Nabriva
Company Location: DUBLIN L2 2
Company CEO: Theodore Schroeder
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lefamulin

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NAB-BC-3781-1014

P1

Completed

Cystic Fibrosis

2022-09-20

Recent News Events

Date

Type

Title

07/18/2024

News Article

 Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics

09/18/2023

News Article

 Lefamulin Market Major Developments and Competition Landscape by 2031

09/18/2023

News Article

 Pleuromutilin Market Growth, Research Scope, Advance Technology and Innovations by 2031

09/12/2023

News Article

 Lefamulin Market Trends Report 2023-2030

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions